Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TV-1106 in Growth Hormone-Deficient Adults
NCT02410343Phase 3Terminated
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Apr 2015
- Primary completion
- Dec 2015
- Modality
- Fc-Fusion Proteins
- Countries
- 7
01
Overview
A Phase 3 trial of albusomatropin in growth hormone deficiency (GHD), sponsored by Teva Pharmaceutical Industries Ltd.. Started Apr 2015; status: terminated.
02
Drugs
albusomatropin
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT02410343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02410343.